Seven Eight Capital LP bought a new position in Qiagen N.V. (NASDAQ:QGEN) in the second quarter, according to its most recent filing with the SEC. The firm bought 7,800 shares of the company’s stock, valued at approximately $262,000.
A number of other hedge funds also recently added to or reduced their stakes in the stock. AJO LP boosted its stake in Qiagen N.V. by 358.3% in the 2nd quarter. AJO LP now owns 45,192 shares of the company’s stock worth $1,515,000 after purchasing an additional 35,331 shares in the last quarter. Alliancebernstein L.P. boosted its stake in Qiagen N.V. by 1.2% in the 2nd quarter. Alliancebernstein L.P. now owns 205,936 shares of the company’s stock worth $6,905,000 after purchasing an additional 2,463 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Qiagen N.V. in the 2nd quarter worth approximately $18,234,000. Oppenheimer Asset Management Inc. boosted its stake in Qiagen N.V. by 0.5% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 3,961 shares of the company’s stock worth $133,000 after purchasing an additional 20 shares in the last quarter. Finally, Bronfman E.L. Rothschild L.P. boosted its stake in Qiagen N.V. by 26.2% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 7,588 shares of the company’s stock worth $254,000 after purchasing an additional 1,574 shares in the last quarter. Institutional investors own 63.01% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Seven Eight Capital LP Takes $262,000 Position in Qiagen N.V. (QGEN)” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.chaffeybreeze.com/2017/09/19/seven-eight-capital-lp-takes-262000-position-in-qiagen-n-v-qgen.html.
QGEN has been the subject of a number of recent analyst reports. Commerzbank Ag reiterated a “buy” rating on shares of Qiagen N.V. in a research note on Friday, June 23rd. Morgan Stanley reiterated an “overweight” rating and issued a $37.00 target price (up from $36.00) on shares of Qiagen N.V. in a research note on Monday, July 10th. Zacks Investment Research upgraded shares of Qiagen N.V. from a “sell” rating to a “hold” rating and set a $38.00 target price for the company in a research note on Wednesday, July 12th. BidaskClub cut shares of Qiagen N.V. from a “buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Finally, Wells Fargo & Company reiterated a “market perform” rating and issued a $31.00 target price (up from $28.00) on shares of Qiagen N.V. in a research note on Thursday, July 13th. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $33.17.
Qiagen N.V. (NASDAQ:QGEN) opened at 32.11 on Tuesday. Qiagen N.V. has a 52-week low of $24.89 and a 52-week high of $35.26. The firm’s 50-day moving average is $31.89 and its 200-day moving average is $31.75. The stock has a market capitalization of $7.33 billion, a price-to-earnings ratio of 98.20 and a beta of 1.15.
Qiagen N.V. (NASDAQ:QGEN) last posted its quarterly earnings data on Thursday, July 27th. The company reported $0.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.28 by $0.02. The business had revenue of $349.00 million during the quarter, compared to the consensus estimate of $353.09 million. Qiagen N.V. had a return on equity of 11.04% and a net margin of 5.44%. The company’s revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.24 earnings per share. Analysts predict that Qiagen N.V. will post $1.21 earnings per share for the current year.
Qiagen N.V. Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NASDAQ:QGEN).
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.